Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differentially Expressed Circular RNAs and their Therapeutic Mechanism in Nonsegmental Vitiligo Patients Treated with Methylprednisolone

ABSTRACT: We identified the differentially expressed circular RNAs in vitiligo patients before and after treatment of methylprednisolone. We have completed the Arraystar Human circRNA Array V2 analysis of the 8 peripheral blood specimens. Whole blood samples (3 mL each) were collected by venipuncture into heparinized vacutainers from a total of four patients diagnosed with nonsegmental vitiligo before and after systemic glucocorticoid therapy (oral methylprednisolone tablets, 12mg daily for eight weeks).

ORGANISM(S): Homo sapiens

PROVIDER: GSE197415 | GEO | 2022/02/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene-expression profiling between segmental vitiligo, generalized vitiligo and healthy individual

Project description:Investigate the gene expression change in the blood of segmental vitiligo, generalized vitiligo and healthy individual.

2016-04-08 | GSE80009 | GEO

Differentially Expressed Circular RNAs and their Therapeutic Mechanism in Nonsegmental Vitiligo Patients Treated with Methylprednisolone

Project description:Differentially Expressed Circular RNAs and their Therapeutic Mechanism in Nonsegmental Vitiligo Patients Treated with Methylprednisolone

| PRJNA810179 | ENA

Single-Cell Transcriptomics Reveals Peripheral Immune Responses in Non-Segmental Vitiligo

Project description:Vitiligo is a common autoimmune depigmented dermatology due to the destruction of melanocytes. Much evidence suggests that vitiligo is associated with systemic immune activation. Previous studies have focused on immune cell infiltration in and around lesion areas, while few studies have investigated the cell types and function of circulating immune cells in peripheral blood. We collected peripheral blood from five patients with progressive non-segmental vitiligo (PV) and three healthy controls (HC).Single-cell RNA sequencing(scRNA-seq) is used to investigate the mechanisms of peripheral immune responses in vitiligo patients.

2023-11-07 | GSE231794 | GEO

Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse

Project description:We analyzed the transcriptome profiles of CD19+ B cells and CD4+ T cells from the peripheral blood of patients with multiple sclerosis (MS) immediately before and after relapse therapy with high-dose methylprednisolone (MP). High-density Clariom D Arrays for human were used to quantify the transcript levels. This GEO entry provides the processed data from the gene-level and exon-level workflows.

2024-02-20 | GSE255952 | GEO

Rat Kidney Methylprednisolone

Project description:Summary: To identify distinct temporal patterns of mRNA expression in the kidney of rats following a bolus dose of the corticosteroid methylprednisolone. Hypothesis: That prednisone pharmacodynamics can be derived from expression profiling data. Keywords: other

2004-09-02 | GSE1721 | GEO

Transcription profiling of skin from vitiligo patients and healthy volunteers reveals the WNT pathway as a target for re-pigmenting vitiligo lesions

Project description:Vitiligo is an acquired depigmentation of the skin inducing a marked alteration of the quality of life of affected individuals. Halting the disease progression and repigmenting the lesional skin represent the two faces of the therapeutic challenge in vitiligo. So far, none of them has been successfully addressed. Oxidative stress and immune system in genetically predisposed individuals participate to the complex pathophysiology of vitiligo. We performed a transcriptome and proteomic analysis on lesional, perilesional and non-depigmented skin of vitiligo patients compared to matched skin controls of healthy subjects. Our results show that the WNT pathway, implicated in melanocytes differentiation, was found to be altered in vitiligo skin. We demonstrated that the oxidative stress decreases WNT expression/activation in keratinocytes and in melanocytes. We developed an ex vivo skin model that remains functional up to 15 days. We then confirmed the decreased activation of the WNT pathway in human skin subjected to oxidative stress. Finally, using pharmacological agents that activate the WNT pathway, we treated the ex vivo depigmented skins from vitiligo patients and successfully induced the differentiation of resident stem cells into pre-melanocytes supporting further exploration of WNT activators to repigment vitiligo lesions. Total of 40 chips. 10 patients (3 biospies per patient: 1 lesional , 1 perilesional and 1 non lesional) ; 10 healthy volunteers (1biopsy in matched anatomical areas)

2015-10-01 | E-GEOD-65127 | biostudies-arrayexpress

Targeting the WNT pathway for repigmenting vitiligo

Project description:Vitiligo is an acquired depigmentation of the skin inducing a marked alteration of the quality of life of affected individuals. Halting the disease progression and repigmenting the lesional skin represent the two faces of the therapeutic challenge in vitiligo. So far, none of them has been successfully addressed. Oxidative stress and immune system in genetically predisposed individuaLesionalparticipate to the complex pathophysiology of vitiligo. We performed a transcriptome and proteomic analysis on lesional, perilesional and non-depigmented skin of vitiligo patients compared to matched skin controLesionalof healthy subjects. Our results show that the WNT pathway, implicated in melanocytes differentiation, was found to be altered in vitiligo skin. We demonstrated that the oxidative stress decreases WNT expression/activation in keratinocytes and in melanocytes. We developed an ex vivo skin model that remains functional up to 15 days. We then confirmed the decreased activation of the WNT pathway in human skin subjected to oxidative stress. Finally, using pharmacological agents that activate the WNT pathway, we treated the ex vivo depigmented skins from vitiligo patients and successfully induced the differentiation of resident stem celLesionalinto pre-melanocytes supporting further exploration of WNT activators to repigment vitiligo lesions.

2015-10-01 | GSE65127 | GEO

Genome-wide analysis of gene expression within vitiligo mouse skin

Project description:Skin samples from mice in a model of vitiligo were selected for gene expression profiling in order to identify active inflammatory pathways. Total RNA isolated from 6 mouse samples from fresh skin, 3 from vitiligo mice and 3 from control mice.

2013-12-12 | E-GEOD-53147 | biostudies-arrayexpress

Genome-wide analysis of gene expression within vitiligo lesional skin with active inflammation

Project description:Vitiligo skin samples with an active inflammatory infiltrate were selected for gene expression profiling in order to identify inflammatory pathways that drive depigmentation in vitiligo. Total RNA was isolated from 10 deidentified human samples from formalin fixed, paraffin-embedded skin, 5 from vitiligo patients and 5 from controls. Control skin was age- and site-matched excision tips without pathology.

2013-12-12 | E-GEOD-53146 | biostudies-arrayexpress

Increased expression of LOC100506314 in T cells from patients with vitiligo and contributed to the pathogenesis of vitiligo

Project description:The aim of this study was to investigate the differential expression of long non-coding RNAs (lncRNAs) in T cells from patients with vitiligo and their roles in the pathogenesis of vitiligo. The expression profiles of the RNA transcripts in T cells from three patients with vitiligo and three controls were conducted using microarray analysis. These aberrantly-expressed genes were further validated using T cells from 41 patients with vitiligo and 28 controls. The biologic function of the specific lncRNAs was investigated using transfection, RNA pull-down assay plus proteomic approach and Western blotting. As the results, the expression levels of 134 genes, were significantly increased, whereas the expression levels 142 genes were significantly decreased in T cells from patients with vitiligo compared with the controls. After selection and validation, the expression levels of 11 genes increased and two genes decreased in T cells from patients with vitiligo. We confirmed that LOC100506314 could interact with the signal transducer and activator of transcription 3 (STAT3) and macrophage migration inhibitory factor (MIF). The transfection of LOC100506314 could suppress STAT3, AKT, and ERK phosphorylation and nuclear protein levels of p65. Finally, overexpressed LOC100506314 decreased the T cell expression of IL-6 and IL-17. In conclusion, among the lncRNAs, we found that the expression levels of LOC100506314 were increased in T cells from patients with vitiligo. LOC100506314 could bind to STAT3 and MIF and suppress the expression of IL-6 and IL-17 through the inhibition of the STAT3, AKT, ERK, and NF-κB pathway. Increased the expression of LOC100506314 in T cells could be a potential therapeutic strategy for vitiligo.

2023-09-27 | GSE205751 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data